Cargando…

Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China

(1) Background: As prescribers, physicians play a decisive role in applying and promoting pharmacogenomic (PGx) testing in clinical practices. So far, little is known about physicians’ perspectives on PGx testing in China. The aim of this study was to assess physicians’ knowledge of, attitude toward...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Tong, Wu, Caiying, Hu, Xiaowen, Li, Sicong, Zhang, Xinyi, Cai, Yuchun, Chen, Jing, Shi, Luwen, Lu, Christine Y., Nie, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783535/
https://www.ncbi.nlm.nih.gov/pubmed/36556242
http://dx.doi.org/10.3390/jpm12122021
_version_ 1784857600352845824
author Jia, Tong
Wu, Caiying
Hu, Xiaowen
Li, Sicong
Zhang, Xinyi
Cai, Yuchun
Chen, Jing
Shi, Luwen
Lu, Christine Y.
Nie, Xiaoyan
author_facet Jia, Tong
Wu, Caiying
Hu, Xiaowen
Li, Sicong
Zhang, Xinyi
Cai, Yuchun
Chen, Jing
Shi, Luwen
Lu, Christine Y.
Nie, Xiaoyan
author_sort Jia, Tong
collection PubMed
description (1) Background: As prescribers, physicians play a decisive role in applying and promoting pharmacogenomic (PGx) testing in clinical practices. So far, little is known about physicians’ perspectives on PGx testing in China. The aim of this study was to assess physicians’ knowledge of, attitude towards, and experience of PGx testing in China. (2) Methods: A 39-question online survey was developed. Participants were physicians recruited through two platforms, MEDLINKER and “Dazhuanjia”. (3) Results: A total of 450 respondents completed the survey and 366 questionnaires were eligible for analysis based on the inclusion criteria. Among all included physicians, 275 (75.1%) had heard of PGx testing before. More than half rated their knowledge of PGx testing as “Fair” (61.5%) while 20.0% chose “Excellent” or “Good” and 18.6% chose “Poor” or “Terrible”. “Guidelines, consensus, and treatment paths for disease diagnosis and treatment” (72.7%) were the most preferred sources of information about PGx testing. Respondents were confident in their personal capacity to conduct PGx, with an average score of 3.30 ± 0.09 (out of 5.00). Most respondents (75.6%) believed that PGx could “help to improve efficacy and reduce the incidence of adverse reactions”. Targeted cancer therapy (score 78.95 ± 1.26 out of 100) was considered the field where PGx testing had its highest value. Lack of professionals and knowledge (n = 186, 67.6%), high costs of testing (n = 170, 61.8%), and lack of hospitals to offer PGx testing (n = 166, 60.4%) were identified as the primary obstacles to increasing the uptake of PGx testing in China. Academic conference (n = 213, 72.4%) was considered the most efficient way for physicians to obtain information about PGx testing. (4) Conclusions: Physicians in China have poor knowledge about PGx testing; nonetheless, they generally had confidence in their capacity to order PGx testing and positive attitudes towards the use of PGx testing in routine clinical practices. Future efforts to promote the uptake of PGx testing should focus on foundational education and practical training.
format Online
Article
Text
id pubmed-9783535
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97835352022-12-24 Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China Jia, Tong Wu, Caiying Hu, Xiaowen Li, Sicong Zhang, Xinyi Cai, Yuchun Chen, Jing Shi, Luwen Lu, Christine Y. Nie, Xiaoyan J Pers Med Article (1) Background: As prescribers, physicians play a decisive role in applying and promoting pharmacogenomic (PGx) testing in clinical practices. So far, little is known about physicians’ perspectives on PGx testing in China. The aim of this study was to assess physicians’ knowledge of, attitude towards, and experience of PGx testing in China. (2) Methods: A 39-question online survey was developed. Participants were physicians recruited through two platforms, MEDLINKER and “Dazhuanjia”. (3) Results: A total of 450 respondents completed the survey and 366 questionnaires were eligible for analysis based on the inclusion criteria. Among all included physicians, 275 (75.1%) had heard of PGx testing before. More than half rated their knowledge of PGx testing as “Fair” (61.5%) while 20.0% chose “Excellent” or “Good” and 18.6% chose “Poor” or “Terrible”. “Guidelines, consensus, and treatment paths for disease diagnosis and treatment” (72.7%) were the most preferred sources of information about PGx testing. Respondents were confident in their personal capacity to conduct PGx, with an average score of 3.30 ± 0.09 (out of 5.00). Most respondents (75.6%) believed that PGx could “help to improve efficacy and reduce the incidence of adverse reactions”. Targeted cancer therapy (score 78.95 ± 1.26 out of 100) was considered the field where PGx testing had its highest value. Lack of professionals and knowledge (n = 186, 67.6%), high costs of testing (n = 170, 61.8%), and lack of hospitals to offer PGx testing (n = 166, 60.4%) were identified as the primary obstacles to increasing the uptake of PGx testing in China. Academic conference (n = 213, 72.4%) was considered the most efficient way for physicians to obtain information about PGx testing. (4) Conclusions: Physicians in China have poor knowledge about PGx testing; nonetheless, they generally had confidence in their capacity to order PGx testing and positive attitudes towards the use of PGx testing in routine clinical practices. Future efforts to promote the uptake of PGx testing should focus on foundational education and practical training. MDPI 2022-12-07 /pmc/articles/PMC9783535/ /pubmed/36556242 http://dx.doi.org/10.3390/jpm12122021 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jia, Tong
Wu, Caiying
Hu, Xiaowen
Li, Sicong
Zhang, Xinyi
Cai, Yuchun
Chen, Jing
Shi, Luwen
Lu, Christine Y.
Nie, Xiaoyan
Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China
title Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China
title_full Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China
title_fullStr Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China
title_full_unstemmed Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China
title_short Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China
title_sort physicians’ knowledge, attitude, and experience of pharmacogenomic testing in china
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783535/
https://www.ncbi.nlm.nih.gov/pubmed/36556242
http://dx.doi.org/10.3390/jpm12122021
work_keys_str_mv AT jiatong physiciansknowledgeattitudeandexperienceofpharmacogenomictestinginchina
AT wucaiying physiciansknowledgeattitudeandexperienceofpharmacogenomictestinginchina
AT huxiaowen physiciansknowledgeattitudeandexperienceofpharmacogenomictestinginchina
AT lisicong physiciansknowledgeattitudeandexperienceofpharmacogenomictestinginchina
AT zhangxinyi physiciansknowledgeattitudeandexperienceofpharmacogenomictestinginchina
AT caiyuchun physiciansknowledgeattitudeandexperienceofpharmacogenomictestinginchina
AT chenjing physiciansknowledgeattitudeandexperienceofpharmacogenomictestinginchina
AT shiluwen physiciansknowledgeattitudeandexperienceofpharmacogenomictestinginchina
AT luchristiney physiciansknowledgeattitudeandexperienceofpharmacogenomictestinginchina
AT niexiaoyan physiciansknowledgeattitudeandexperienceofpharmacogenomictestinginchina